Moreover, IDH1 knockdown increased the response to ibrutinib in a subcutaneous xenograft model of DLBCL, by attenuating αKG and GSH production and increasing ROS levels [65]. The gene discussed is IDH1; the disease is diffuse large B-cell lymphoma.